Echelon’s fluorogenic Autotaxin (ATX) substrate FS-3 (L-2000) is a doubly labeled analog of LPC wherin the fluorophore is quenched through intramolecular energy transfer. Hydrolysis of the substrate produces an increase in fluorescence.
Autotaxin which has lysophospholipase D (lysoPLD) activity, cleaves choline from lysophosphatidylcholine forming lysophosphatidic acid (LPA), a potent mitogen that as been implicated in the pathophysiology of ovarian cancer. LysoPLD/ATX has been demonstrated to increase cell motility, neovascularization, proliferation, and aggressiveness of tumors and is upregulated in numerous cancer lineages (non-small cell lung , glioma, mammary carcinoma, renal cell carcinoma, hepatocellular carcinoma). In addition, dysregulation of the ATX/LPA pathway is central to the pathophysiology of idiopathic pulmonary fibrosis, rheumatoid arthritis, and other inflammatory diseases. Modulation of ATX activity through small-molecules is a target with high potential for novel cancer and anti-inflammatory therapeutics.
Notice to Purchaser: Echelon Biosciences products are sold for research and development purposes only and are not to be incorporated into products for resale without written permission from Echelon Biosciences. The compound FS-3 and its use in assaying for Lysophospholipase D activity are covered by Echelon Biosciences Inc. US patents 7,459,285 & 7,989,663. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser’s own internal research. For inquiries email email@example.com